Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent low blood glucose levels. It has announced that it has closed a US$21 million Series A Financing led by Perceptive Xontogeny Venture Fund.
Zucara will use the funding for Phase 1 and Phase 2 clinical trials of ZT-01, the company’s first-in-class drug candidate designed to prevent low blood glucose levels in Type 1 Diabetes.